Citadel Advisors
PTGX icon

Citadel Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Citadel Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$390K Sell
3,700
-2,700
-42% -$239K ﹤0.01% 9870
2025
Q4 		$559K Buy
6,400
+200
+3% +$16.4K ﹤0.01% 8758
2025
Q3 		$412K Sell
6,200
-12,400
-67% -$705K ﹤0.01% 9598
2025
Q2 		$1.03M Sell
18,600
-17,500
-48% -$840K ﹤0.01% 7023
2025
Q1 		$1.75M Buy
36,100
+8,000
+28% +$335K ﹤0.01% 5797
2024
Q4 		$1.08M Buy
28,100
+16,300
+138% +$711K ﹤0.01% 6843
2024
Q3 		$531K Buy
11,800
+4,200
+55% +$170K ﹤0.01% 8133
2024
Q2 		$263K Sell
7,600
-6,800
-47% -$199K ﹤0.01% 9397
2024
Q1 		$417K Sell
14,400
-40,600
-74% -$1.1M ﹤0.01% 8780
2023
Q4 		$1.26M Buy
55,000
+30,500
+124% +$534K ﹤0.01% 6234
2023
Q3 		$409K Sell
24,500
-52,900
-68% -$1.03M ﹤0.01% 8511
2023
Q2 		$2.14M Sell
77,400
-4,900
-6% -$123K ﹤0.01% 5038
2023
Q1 		$1.89M Buy
82,300
+57,600
+233% +$967K ﹤0.01% 5496
2022
Q4 		$269K Buy
+24,700
New +$208K ﹤0.01% 9549
2022
Q3 		– Sell
-40,300
Closed -$319K – 13398
2022
Q2 		$319K Sell
40,300
-9,200
-19% -$111K ﹤0.01% 9673
2022
Q1 		$1.17M Buy
49,500
+7,800
+19% +$220K ﹤0.01% 7344
2021
Q4 		$1.43M Sell
41,700
-181,500
-81% -$5.74M ﹤0.01% 7005
2021
Q3 		$3.96M Buy
223,200
+210,800
+1,700% +$8.99M ﹤0.01% 4767
2021
Q2 		$557K Buy
+12,400
New +$409K ﹤0.01% 9823

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Citadel Advisors's PTGX Position: Q1 2026 in Review

Citadel Advisors increased its Protagonist Therapeutics (PTGX) stake by 38% in Q1 2026, buying an estimated $37.6M and bringing the position to 1,551,900 shares worth $164M. The position accounts for 0.03% of the portfolio, ranked #545.

Citadel Advisors first reported a position in PTGX in Q1 2018 and has held it in 30 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Citadel Advisors held 1,551,900 shares of Protagonist Therapeutics worth $164M as of Q1 2026.
  • Citadel Advisors bought 425,213 Protagonist Therapeutics shares in Q1 2026, an estimated $37.6M.
  • Protagonist Therapeutics made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #545 holding.
  • Citadel Advisors first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 30 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.